Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at TD Cowen Treatment Advancements in Obesity and Related Disorders Summit Transcript [Seeking Alpha]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, and thank you for joining us at TD Cowen's 2025 Treatment Advances in Obesity Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen. And it is my pleasure to have with me today Dr. James Hamilton, who is the Chief Medical Officer and Head of Research and Development of Arrowhead Pharmaceuticals. So thanks for joining us. Maybe before we get into some of the specific programs, it might be helpful just to level set and kick off the discussion with just a brief overview of Arrowhead's recent progress and accomplishments. Obviously, we saw the update on the Sarepta partnership this morning, which is great to see. And then maybe what should investors be expecting into the end of the year and into 2026? And then we can kind of go fro
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe HypertriglyceridemiaBusiness Wire
- Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 ConferencesBusiness Wire
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a "buy" rating on the stock.MarketBeat
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.MarketBeat
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 12/5/25 - Form 144
- 12/1/25 - Form 4
- 11/28/25 - Form 144
- ARWR's page on the SEC website